{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:22:32Z","timestamp":1740147752837,"version":"3.37.3"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T00:00:00Z","timestamp":1501632000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s11739-017-1713-x","type":"journal-article","created":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T01:13:57Z","timestamp":1501636437000},"page":"1093-1099","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The benefit of angiotensin AT1 receptor blockers for early treatment of hypertensive patients"],"prefix":"10.1007","volume":"12","author":[{"given":"Bruno","family":"Trimarco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciro","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0311-9069","authenticated-orcid":false,"given":"Maurizio","family":"Galderisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,2]]},"reference":[{"key":"1713_CR1","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","volume":"34","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, B\u00f6hm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F (2013) 2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34:2159\u20132219","journal-title":"Eur Heart J"},{"key":"1713_CR2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11739-016-1527-2","volume":"12","author":"D Rendina","year":"2017","unstructured":"Rendina D, Ippolito R, De Filippo G, Muscariello R, De Palma D, De Bonis S, Schiano di Cola M, Benvenuto D, Galderisi M, Strazzullo P, Galletti F, Strazzullo P, Galletti F (2017) Risk factors for silent ischemia in patients with well established essential hypertension. Intern Emerg Med 12:171\u2013179","journal-title":"Intern Emerg Med"},{"key":"1713_CR3","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahlof","year":"2002","unstructured":"Dahlof B, Devereux RB, Kjeldsen SE, Julius S, For the LIFE (Losartan Intervention for Endpoint Reduction) Study Group (2002) Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction (LIFE): a randomised trial against atenolol. Lancet 359:995\u20131003","journal-title":"Lancet"},{"key":"1713_CR4","doi-asserted-by":"crossref","first-page":"s173","DOI":"10.1097\/01.ASN.0000032549.36050.78","volume":"13","author":"M Volpe","year":"2002","unstructured":"Volpe M, Savoia C, De Paolis P, Ostrowska B, Tarasi D, Rubattu S (2002) The renin\u2013angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease. J Am Soc Nephrol 13:s173\u2013S178","journal-title":"J Am Soc Nephrol"},{"key":"1713_CR5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s40292-015-0120-5","volume":"22","author":"C Borghi","year":"2015","unstructured":"Borghi C, Task Force SIIA, Rossi F, SIF Task Force (2015) Role of the renin\u2013angiotensin\u2013aldosterone system and its pharmacological inhibitors in cardiovascular diseases: complex and critical issues. High Blood Press Cardiovasc Prev 22:429\u2013444","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"1713_CR6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ijcard.2015.07.051","volume":"199","author":"G Savarese","year":"2015","unstructured":"Savarese G, Edner M, Dahlstr\u00f6m U, Perrone-Filardi P, Hage C, Cosentino F, Lund LH (2015) Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction. Int J Cardiol 199:415\u2013423","journal-title":"Int J Cardiol"},{"key":"1713_CR7","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.jacc.2016.01.050","volume":"67","author":"M Evans","year":"2016","unstructured":"Evans M, Carrero JJ, Szummer K, \u00c5kerblom A, Edfors R, Spaak J, Jacobson SH, Andell P, Lindhagen L, Jernberg T (2016) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in myocardial infarction patients with renal dysfunction. J Am Coll Cardiol 67:1687\u20131697","journal-title":"J Am Coll Cardiol"},{"key":"1713_CR8","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jacc.2013.10.050","volume":"63","author":"MZ Molnar","year":"2014","unstructured":"Molnar MZ, Kalantar-Zadeh K, Lott EH, Lu JL, Malakauskas SM, Ma JZ, Quarles DL, Kovesdy CP (2014) Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease. J Am Coll Cardiol 63:650\u2013658","journal-title":"J Am Coll Cardiol"},{"key":"1713_CR9","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"The Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) Investigators","year":"2008","unstructured":"The Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) Investigators (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547\u20131559","journal-title":"N Engl J Med"},{"key":"1713_CR10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"The Heart Outcomes Prevention Evaluation Study (HOPE) Investigators","year":"2000","unstructured":"The Heart Outcomes Prevention Evaluation Study (HOPE) Investigators (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145\u2013153","journal-title":"N Engl J Med"},{"key":"1713_CR11","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","volume":"353","author":"L Hansson","year":"1999","unstructured":"Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanm\u00e4ki K, Dahl\u00f6f B, de Faire U, M\u00f6rlin C, Karlberg BE, Wester PO, Bj\u00f6rck JE (1999) Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353:611\u2013666","journal-title":"Lancet"},{"key":"1713_CR12","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"ALLHAT Collaborative Research Group","year":"2002","unstructured":"ALLHAT Collaborative Research Group (2002) Major outcomes in high risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 288:2981\u20132995","journal-title":"JAMA"},{"key":"1713_CR13","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMoa021716","volume":"348","author":"MH Lindon","year":"2003","unstructured":"Lindon MH, Wing MB, Reid CM, Ryan P, Beilin LJ, Brown MA, For the Second Australian National Blood Pressure Study Group (2003) A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348:583\u2013592","journal-title":"N Engl J Med"},{"issue":"366","key":"1713_CR14","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"16","author":"B Dahl\u00f6f","year":"2005","unstructured":"Dahl\u00f6f B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O\u2019Brien E, Ostergren J, ASCOT Investigators (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 16(366):895\u2013906","journal-title":"Lancet"},{"key":"1713_CR15","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","volume":"358","author":"NS Beckett","year":"2008","unstructured":"Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ, HYVET Study Group (2008) Treatment of hypertension in patients 80\u00a0years of age or older. N Engl J Med 358:1887\u20131898","journal-title":"N Engl J Med"},{"key":"1713_CR16","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","volume":"363","author":"S Julius","year":"2004","unstructured":"Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 363:2022\u20132031","journal-title":"Lancet"},{"key":"1713_CR17","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/01.STR.0000166048.35740.a9","volume":"36","author":"J Schrader","year":"2005","unstructured":"Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC, MOSES Study Group (2005) Morbidity and mortality after stroke. Eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 36:1218\u20131226","journal-title":"Stroke"},{"key":"1713_CR18","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s11739-016-1435-5","volume":"11","author":"F Viazzi","year":"2016","unstructured":"Viazzi F, Bonino B, Cappadona E, Pontremoli R (2016) Renin angiotensin-aldosterone system blockade in chronic kidney disease: current strategies and look ahead. Intern Emerg Med 11:627\u2013635. Intern Emerg Med 11:627\u2013635","journal-title":"Intern Emerg Med"},{"key":"1713_CR19","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456\u20131462","journal-title":"N Engl J Med"},{"key":"1713_CR20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","volume":"354","author":"FF Hou","year":"2006","unstructured":"Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW (2006) Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 354:131\u2013140","journal-title":"N Engl J Med"},{"key":"1713_CR21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/clc.4960240303","volume":"24","author":"P Carson","year":"2001","unstructured":"Carson P, Giles T, Higginbotham M, Hollenberg N, Kannel W, Siragy HM (2001) Angiotensin receptor blockers: evidence for preserving target organs. Clin Cardiol 24:183\u2013190","journal-title":"Clin Cardiol"},{"key":"1713_CR22","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1253\/circj.CJ-16-0577","volume":"80","author":"M Miura","year":"2016","unstructured":"Miura M, Sakata Y, Miyata S, Shiba N, Takahashi J, Nochioka K, Takada T, Saga C, Shinozaki T, Sugi M, Nakagawa M, Sekiguchi N, Komaru T, Kato A, Fukuchi M, Nozaki E, Hiramoto T, Inoue K, Goto T, Ohe M, Tamaki K, Ibayashi S, Ishide N, Maruyama Y, Tsuji I, Shimokawa H, SUPPORT Trial Investigators (2016) Influence of left ventricular ejection fraction on the effects of supplemental use of angiotensin receptor blocker olmesartan in hypertensive patients with heart failure. Circ J 80:2155\u20132164","journal-title":"Circ J"},{"key":"1713_CR23","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","volume":"364","author":"H Haller","year":"2011","unstructured":"Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G, ROADMAP Trial Investigators (2011) Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 364:907\u2013917","journal-title":"N Engl J Med"},{"key":"1713_CR24","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","volume":"351","author":"AH Barnett","year":"2004","unstructured":"Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, For the Diabetic Exposed to Telmisartan and Enalapril Study Group (2004) Angiotensin-receptor versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351:1952\u20131961","journal-title":"N Engl J Med"},{"key":"1713_CR25","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2165\/11591350-000000000-00000","volume":"71","author":"G Tocci","year":"2011","unstructured":"Tocci G, Volpe M (2011) End-organ protection in patients with hypertension: focus on the role of angiotensin receptor blockers on renal function. Drugs 71:1003\u20131017","journal-title":"Drugs"},{"key":"1713_CR26","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(97)01187-2","volume":"349","author":"B Pitt","year":"1997","unstructured":"Pitt B, Segal R, Martinez FA (1997) Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet 349:747\u2013752","journal-title":"Lancet"},{"key":"1713_CR27","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","volume":"355","author":"B Pitt","year":"2000","unstructured":"Pitt B, Poole-Wilson PA, Segal R (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2014the Losartan Heart Failure Survival study\u2014ELITE II. Lancet 355:1582\u20131587","journal-title":"Lancet"},{"key":"1713_CR28","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","volume":"360","author":"K Dickstein","year":"2002","unstructured":"Dickstein K, Kjekshus J, OPTIMAAL Steering Committee for the OPTIMAAL Study Group (2002) Effects of losartan and captopril on mortality and morbidity in high risk patients after acute myocardial infarction: the OPTIMAL randomised trial. Lancet 360:752\u2013760","journal-title":"Lancet"},{"key":"1713_CR29","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","volume":"349","author":"M Pfeffer","year":"2003","unstructured":"Pfeffer M, Mc Murray J, Velasquez E, Rouleau J-L, Kober L, Maggioni AP, For the VALIANT Investigators (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction or both. N Engl J Med 349:1893\u20131906","journal-title":"N Engl J Med"},{"key":"1713_CR30","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","volume":"362","author":"The EURopean trial On reduction of cardiac events with perindopril instable coronary Artery disease Investigators","year":"2003","unstructured":"The EURopean trial On reduction of cardiac events with perindopril instable coronary Artery disease Investigators (2003) Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362:782\u2013788","journal-title":"Lancet"},{"key":"1713_CR31","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","volume":"333","author":"L K\u00f8ber","year":"1995","unstructured":"K\u00f8ber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC (1995) A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 333:1670\u20131676","journal-title":"N Engl J Med"},{"key":"1713_CR32","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0735-1097(99)00634-8","volume":"35","author":"L Kj\u00f8ller-Hansen","year":"2000","unstructured":"Kj\u00f8ller-Hansen L, Steffensen R, Grande P (2000) The angiotensin-converting enzyme inhibition post revascularization study (APRES). J Am Coll Cardiol 35:881\u2013888","journal-title":"J Am Coll Cardiol"},{"key":"1713_CR33","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1161\/01.CIR.90.4.1731","volume":"90","author":"JD Rutherford","year":"1994","unstructured":"Rutherford JD, Pfeffer MA, Moy\u00e9 LA, Davis BR, Flaker GC, Kowey PR, Lamas GA, Miller HS, Packer M, Rouleau JL (1994) Effects of captopril on ischemic events after myocardial infarction. Results of the survival and ventricular enlargement trial. SAVE Investigators. Circulation 90:1731\u20131738","journal-title":"Circulation"},{"key":"1713_CR34","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1056\/NEJM199209033271002","volume":"327","author":"K Swedberg","year":"1992","unstructured":"Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryd\u00e9n L, Wedel H (1992) Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 327:678\u2013684","journal-title":"N Engl J Med"},{"key":"1713_CR35","first-page":"821","volume":"342","author":"The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","year":"1993","unstructured":"The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators (1993) Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342:821\u2013828","journal-title":"Lancet"},{"key":"1713_CR36","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa042739","volume":"351","author":"E Braunwald","year":"2004","unstructured":"Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh NL, Hsia J, Pfeffer MA, Rice MM, Rosenberg YD, Rouleau JL (2004) Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351:2058\u20132068","journal-title":"N Engl J Med"},{"key":"1713_CR37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00151642-200815020-00002","volume":"15","author":"M Volpe","year":"2008","unstructured":"Volpe M (2008) A new option for therapeutic management of patients with cardiovascular disease. High Blood Press Cardiovasc Prev 15:47\u201351","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"1713_CR38","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1097\/00004872-199917120-00014","volume":"17","author":"A Cuocolo","year":"1999","unstructured":"Cuocolo A, Storto G, Izzo R, De Luca N, Trimarco B (1999) Effects of valsartan on left ventricular diastolic function in patients with mild or moderate essential hypertension: comparison with enalapril. J Hypertens 17:1759\u20131766","journal-title":"J Hypertens"},{"key":"1713_CR39","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/S0140-6736(07)60980-5","volume":"369","author":"SD Solomon","year":"2007","unstructured":"Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, Lacourci\u00e8re Y, Hippler SE, Fields H, Naqvi TZ, Mulvagh SL, Arnold JM, Thomas JD, Zile MR, Aurigemma GP, Valsartan In Diastolic Dysfunction (VALIDD) Investigators (2007) Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet 369:2079\u20132087","journal-title":"Lancet"},{"key":"1713_CR40","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1097\/HJH.0000000000000313","volume":"32","author":"U Raff","year":"2014","unstructured":"Raff U, Ott C, Ruilope LM, Menne J, Haller H, Schmieder RE (2014) Prevention of electrocardiographic\u00a0left\u00a0ventricular\u00a0remodeling by the angiotensin receptor blocker\u00a0olmesartan\u00a0in patients with type 2 diabetes. J Hypertens 32:2267\u20132276","journal-title":"J Hypertens"},{"key":"1713_CR41","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/01.hjh.0000165623.72310.dd","volume":"suppl 23","author":"V Dzau","year":"2005","unstructured":"Dzau V (2005) The cardiovascular continuum and renin\u2013angiotensin\u2013aldosterone system blockade. J Hypertens suppl 23:S9\u2013S17","journal-title":"J Hypertens"},{"key":"1713_CR42","doi-asserted-by":"crossref","first-page":"e28501","DOI":"10.1371\/journal.pone.0028501","volume":"6","author":"S Ahmad","year":"2011","unstructured":"Ahmad S, Simmons T, Varagic J, Moniwa N, Chappell MC, Ferrario CM (2011) Chymase-dependent generation of angiotensin II from angiotensin-(1\u201312) in human atrial tissue. PLoS ONE 6:e28501","journal-title":"PLoS ONE"},{"key":"1713_CR43","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"JN Cohn","year":"2001","unstructured":"Cohn JN, Tognoni G (2001) A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667\u20131675","journal-title":"N Engl J Med"},{"key":"1713_CR44","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, CHARM Investigators Committees (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 362:777\u2013781","journal-title":"Lancet"},{"key":"1713_CR45","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1152\/physrev.00036.2005","volume":"86","author":"M Paul","year":"2006","unstructured":"Paul M, Poyan Mehr A, Kreutz R (2006) Physiology of local renin-angiotensin systems. Physiol Rev 86:747\u2013803","journal-title":"Physiol Rev"},{"key":"1713_CR46","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/HJH.0b013e3282f4edd7","volume":"26","author":"G Corrao","year":"2008","unstructured":"Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, Cesana G, Mancia G (2008) Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 26:819\u2013824","journal-title":"J Hypertens"},{"key":"1713_CR47","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/01.hjh.0000226211.95936.f5","volume":"24","author":"TA Burke","year":"2006","unstructured":"Burke TA, Sturkenboom MC, Lu S-E, Wentworth CE, Lin Y, Rhoads GG (2006) Discontinuation of hypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens 24:1193\u20131200","journal-title":"J Hypertens"},{"key":"1713_CR48","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/sj.jhh.1001873","volume":"19","author":"C Bourgault","year":"2005","unstructured":"Bourgault C, Senecal M, Brisson M, Marentette MA, Gregoire JP (2005) Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens 19:607\u2013613","journal-title":"J Hum Hypertens"},{"key":"1713_CR49","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1097\/00004872-200309000-00011","volume":"21","author":"A Benetos","year":"2003","unstructured":"Benetos A, Thomas F, Bean KE, Guize L (2003) Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population. J Hypertens 21:1635\u20131640","journal-title":"J Hypertens"},{"key":"1713_CR50","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1161\/01.HYP.0000259104.60878.43","volume":"49","author":"J Redon","year":"2007","unstructured":"Redon J, Cea-Calvo L, Lozano JV, Marti-Canales JC, Llisterri JL, Aznar J, Gonz\u00e1lez-Esteban J, PREV-ICTUS Study (2007) Differences in blood pressure control and stroke mortality across Spain: the Prevencion de Riesgo de Ictus (PREV-ICTUS) study. Hypertension 49:799\u2013805","journal-title":"Hypertension"},{"key":"1713_CR51","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40292-013-0007-2","volume":"20","author":"M Volpe","year":"2013","unstructured":"Volpe M, Agabiti Rosei E (2013) 2012 consensus document of the Italian Society of Hypertension (SIIA): strategies to improve blood pressure control in Italy. High Blood Press Cardiovasc Prev 20:45\u201352","journal-title":"High Blood Press Cardiovasc Prev"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11739-017-1713-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-017-1713-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-017-1713-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,16]],"date-time":"2017-11-16T08:14:57Z","timestamp":1510820097000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11739-017-1713-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,2]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1713"],"URL":"https:\/\/doi.org\/10.1007\/s11739-017-1713-x","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"type":"print","value":"1828-0447"},{"type":"electronic","value":"1970-9366"}],"subject":[],"published":{"date-parts":[[2017,8,2]]}}}